Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma
Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma
复制标题
DOI：
10.1016/j.cca.2013.04.026
复制
发表时间：
2013-08-23
影响因子：
5
通讯作者：
Tu, Hong
中科院分区：
文献类型：
--
作者：
Chen, Min;Li, Guohua;Tu, Hong
Background: Glypican-3 (GPO) is a novel histochemical marker of hepatocellular carcinoma (HCC). However, its utility as a serologic marker for HCC is not conclusive. Methods: A total of 1037 subjects, including 155 patients with HCC, 180 with chronic hepatitis, 124 with liver cirrhosis, 442 with non-HCC cancer and 136 healthy controls, were analyzed for serum GPO (sGPC3) by an ELISA constructed with 2 monoclonal antibodies. Results: The average level of sGPO in HCC patients was 99.94 2672 ng/ml, which was significantly higher than in patients with chronic hepatitis (10.45 46.02 ng/ml, P < 0.0001), liver cirrhosis (19.44 50.88 ng/ml, P = 0.0013), non-HCC cancer (20.50 9833 ng/ml, P < 0.0001) and healthy controls (4.14 31.65 ng/ml, P < 0.0001). The sensitivity of sGPO in HCC diagnosis was 40.0%, whereas the specificity was 98.5%, 94.4% and 87.1% in healthy controls, chronic hepatitis patients and liver cirrhosis patients, respectively. In addition, 13.5% (28/207) of lung cancer patients and 13.2% (9/68) of thyroid cancer patients had positive results with sGPC3. Conclusion: Serum GPO is a potential marker for HCC. However, the presence of 5GPC3 in patients with lung cancer and thyroid cancer might limit its application as a single marker in the diagnosis of HCC 0 2013 Elsevier B.V. All rights reserved.
